Advanced SARS-CoV-2 vaccine candidates

Vaccine nameClinical trial number*ManufacturePhase trialNumber of participantsImmunity responseEfficacyRef.
mRNA-1273NCT04470427MODERNA/NIAID330,000CD4+ T cell activation reported Th1 skewed phenotype94.10%[71]
BNT 162b2NCT04368728BioNTech/Pfizer344,000Virus specific Th1 and CD8+ T cell responses reported95%[71]
Ad5-nCoVNCT04526990CanSino Biological340,000T cell responses were observed in 88% of the participants-[71, 72]
AZD1222NCT04540393AstraZeneca330,000T cell responses observed in all participants62.10%[71, 73]
Sputnik VNCT04530396Gamaleya Research Institute340,000CD4+ and CD8+ T cell responses were observed in all participants-[71]
JNJ-78436735NCT04505722Janssen Pharmaceutical390,000CR4+ T cell responses in 80% of the participants-[71, 75]
53coronaVacNCT04456596Sinovac Research & Development Co.38,870Not reported-[71, 73]
BBIBP-CorVNCT04560881Beijing Institute of Biotechnology363,000Not reported79.38%[71, 74]
BBV152CTRI/2020/11/028976Bharat Biotech326,000Virus specific CD4+ and CD8+ T cell responses reported-[71, 73]
NVX-CoV2373NCT04611802Novavax345,000CD4+ T cell activation in all tested participants-[71, 75]
CoVLPNCT04636697Medicago330,612Not reported-[71, 76]

Ref.: reference. “-” in the efficacy column mentioned in Table 3 refers to the lack of information/data on that specific vaccine. Information on these clinical trials can be retrieved from https://clinicaltrials.gov/ct2/home